Literature DB >> 27034070

The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.

Bharathi V Reddy1, Arlene B Chapman2.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder. It is characterized by the development of renal cysts and kidney enlargement and ultimately leads to renal failure typically in the sixth decade of life. Although most patients are asymptomatic until well into adulthood, renal cysts develop much earlier, often in utero. Significant renal anatomic and cystic expansion typically occurs before clinical manifestations in children and young adults with AKPKD. The cyst burden detected by imaging represents the minority of cyst burden, and renal and cardiovascular abnormalities are the most common manifestations in children with ADPKD. Here we review the molecular pathogenesis of ADPKD, discuss the screening, diagnosis and clinical manifestations of this renal disorder in childhood and adolescents and review treatment options and potential therapies currently being tested.

Entities:  

Keywords:  ADPKD; Adolescents; Children; Hypertension; Total kidney volume

Mesh:

Year:  2016        PMID: 27034070     DOI: 10.1007/s00467-016-3364-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  102 in total

1.  Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families.

Authors:  O Z DALGAARD
Journal:  Acta Med Scand Suppl       Date:  1957

2.  Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.

Authors:  A B Chapman; A M Johnson; S Rainguet; K Hossack; P Gabow; R W Schrier
Journal:  J Am Soc Nephrol       Date:  1997-08       Impact factor: 10.121

3.  Intracranial aneurysms and dolichoectasia in autosomal dominant polycystic kidney disease.

Authors:  Stefan Graf; Alexander Schischma; Knut E Eberhardt; Roland Istel; Birgit Stiasny; Bernd D Schulze
Journal:  Nephrol Dial Transplant       Date:  2002-05       Impact factor: 5.992

4.  Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Jared J Grantham; Arlene B Chapman; Michal Mrug; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Diego Martin; Mark E Lockhart; William M Bennett; Marva Moxey-Mims; Kaleab Z Abebe; Yan Lin; James E Bost
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 8.237

5.  Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population.

Authors:  Catherine L Kelleher; Kim K McFann; Ann M Johnson; Robert W Schrier
Journal:  Am J Hypertens       Date:  2004-11       Impact factor: 2.689

Review 6.  Renal stone disease in autosomal dominant polycystic kidney disease.

Authors:  V E Torres; D M Wilson; R R Hattery; J W Segura
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

7.  Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state.

Authors:  Alberto Martinez-Vea; Alfredo Bardaj; Cristina Gutierrez; Carmen Garca; Carmen Peralta; Luis Marcas; Jesús Angel Oliver
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

8.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

9.  Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease.

Authors:  Filip Fencl; Jan Janda; Kveta Bláhová; Zdenek Hríbal; Jitka Stekrová; Alena Puchmajerová; Tomás Seeman
Journal:  Pediatr Nephrol       Date:  2009-02-05       Impact factor: 3.714

10.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Authors:  Anna Caroli; Norberto Perico; Annalisa Perna; Luca Antiga; Paolo Brambilla; Antonio Pisani; Bianca Visciano; Massimo Imbriaco; Piergiorgio Messa; Roberta Cerutti; Mauro Dugo; Luca Cancian; Erasmo Buongiorno; Antonio De Pascalis; Flavio Gaspari; Fabiola Carrara; Nadia Rubis; Silvia Prandini; Andrea Remuzzi; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Lancet       Date:  2013-08-21       Impact factor: 79.321

View more
  15 in total

1.  3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease.

Authors:  Luc Breysem; Stéphanie De Rechter; Frederik De Keyzer; Maria Helena Smet; Bert Bammens; Maria Van Dyck; Maarten Hofmans; Raymond Oyen; Elena Levtchenko; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-01-06       Impact factor: 3.714

2.  Prevalence of Hypertension in Children with Early-Stage ADPKD.

Authors:  Laura Massella; Djalila Mekahli; Dušan Paripović; Larisa Prikhodina; Nathalie Godefroid; Anna Niemirska; Ayşe Ağbaş; Karolina Kalicka; Augustina Jankauskiene; Malgorzata Mizerska-Wasiak; Alberto Caldas Afonso; Rémi Salomon; Georges Deschênes; Gema Ariceta; Z Birsin Özçakar; Ana Teixeira; Ali Duzova; Jérôme Harambat; Tomáš Seeman; Gabriela Hrčková; Adrian Catalin Lungu; Svetlana Papizh; Amira Peco-Antic; Stéphanie De Rechter; Ugo Giordano; Marietta Kirchner; Teresa Lutz; Franz Schaefer; Olivier Devuyst; Elke Wühl; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-19       Impact factor: 8.237

3.  Early cardiovascular manifestations in children and adolescents with autosomal dominant polycystic kidney disease: a single center study.

Authors:  Vasiliki Karava; Cherine Benzouid; Julien Hogan; Claire Dossier; André Pierre Denjean; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2018-05-17       Impact factor: 3.714

4.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

5.  Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience

Authors:  Belde Kasap Demir; Fatma Mutlubaş; Eren Soyaltın; Caner Alparslan; Merve Arya; Demet Alaygut; Seçil Arslansoyu Çamlar; Afig Berdeli; Önder Yavaşcan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 6.  Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

Authors:  Fei Liu; Chunyue Feng; Huijun Shen; Huaidong Fu; Jianhua Mao
Journal:  Kidney Dis (Basel)       Date:  2021-07-02

Review 7.  Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

Authors:  Stéphanie De Rechter; Luc Breysem; Djalila Mekahli
Journal:  Front Pediatr       Date:  2017-12-20       Impact factor: 3.418

8.  European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.

Authors:  Tess Harris; Richard Sandford
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992

9.  Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease.

Authors:  Stéphanie De Rechter; Jonathan Kringen; Peter Janssens; Max Christoph Liebau; Koenraad Devriendt; Elena Levtchenko; Carsten Bergmann; François Jouret; Bert Bammens; Pascal Borry; Franz Schaefer; Djalila Mekahli
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

Review 10.  Urologic Diseases Germane to the Medical Renal Biopsy: Review of a Large Diagnostic Experience in the Context of the Renal Architecture and Its Environs.

Authors:  Stephen M Bonsib
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.